AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38824941 — intervention group
Group type: COMPARATOR
Intervention: standard therapy
Number of subjects: 425
Study 38824959 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor-derived cell-free DNA (dd-cfDNA)
Number of subjects: 2882
Study 38824959 — intervention group
Group type: COMPARATOR
Intervention: Inclusion of dd-cfDNA to standard of care prediction model
Number of subjects: 2882
Study 38825005 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine (80 mg intravenous)
Number of subjects: 110
Study 38825005 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline solution)
Number of subjects: 110
Study 38825014 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy density food (>3.0 kcal/g)
Number of subjects: 66
Study 38825014 — intervention group
Group type: COMPARATOR
Intervention: Medium energy density food (1.7-2.0 kcal/g)
Number of subjects: 66
Study 38825014 — intervention group
Group type: COMPARATOR
Intervention: Low energy density food (∼1.0 kcal/g)
Number of subjects: 66
Study 38825014 — intervention group
Group type: COMPARATOR
Intervention: Later energy intake (post-meal energy intake)
Number of subjects: 66
Study 38825182 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning models based on physical examination (Classic Model)
Number of subjects: 400
Study 38825182 — intervention group
Group type: COMPARATOR
Intervention: Machine learning models based on ultrasound measurements
Number of subjects: 400
Study 38825182 — intervention group
Group type: EXPERIMENTAL
Intervention: Univariate analysis of predictor variables
Number of subjects: 400
Study 38825184 — intervention group
Group type: EXPERIMENTAL
Intervention: PortionSize
Number of subjects: 43
Study 38825184 — intervention group
Group type: COMPARATOR
Intervention: MyFitnessPal (MFP)
Number of subjects: 43
Study 38825333 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialised mood disorder clinic treatment combining evidence-based pharmacological treatment with group psychoeducation
Number of subjects: 158
Study 38825333 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 158
Study 38825333 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialised mood disorder clinic treatment
Number of subjects: 158
Study 38825359 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (TOF)
Number of subjects: 372
Study 38825359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 38825603 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic insertion (RobOtol, Colin, France)
Number of subjects: 37
Study 38825603 — intervention group
Group type: COMPARATOR
Intervention: Conventional insertion
Number of subjects: 37
Study 38825627 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg
Number of subjects: 524
Study 38825627 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab emtansine (T-DM1) 3.6 mg/kg
Number of subjects: 524
Study 38825627 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events for T-DXd
Number of subjects: 524
Study 38825627 — intervention group
Group type: COMPARATOR
Intervention: Treatment-emergent adverse events for T-DM1
Number of subjects: 524
Study 38825628 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic Stage (PS)
Number of subjects: 6924
Study 38825628 — intervention group
Group type: COMPARATOR
Intervention: Anatomic Stage (AS)
Number of subjects: 6924
Study 38825688 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary endarterectomy (PEA), Balloon pulmonary angioplasty (BPA), and targeted medical therapy
Number of subjects: 1500
Study 38825840 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated atlas-based volumetry (44 regions)
Number of subjects: 508
Study 38825840 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated planimetric measures of brainstem regions
Number of subjects: 508
Study 38825840 — intervention group
Group type: EXPERIMENTAL
Intervention: Staging systems
Number of subjects: 508
Study 38825840 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 508
Study 38825999 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based biodex balance exercise system (BBS) performed twice weekly for 8 weeks
Number of subjects: 32
Study 38825999 — intervention group
Group type: COMPARATOR
Intervention: Control group received information regarding diabetes self-management
Number of subjects: 32
Study 38826207 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine support (Anesthesiology Control Tower - ACT)
Number of subjects: 71927
Study 38826207 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 71927
Study 38826207 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine support (ACT)
Number of subjects: 71927
Study 38826330 — intervention group
Group type: EXPERIMENTAL
Intervention: Seclidemstat (SP-2577)
Number of subjects: 0
Study 38826330 — intervention group
Group type: COMPARATOR
Intervention: SP-2509 (noncompetitive inhibitor)
Number of subjects: 0
Study 38826341 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond consumption for 8 weeks
Number of subjects: 73
Study 38826341 — intervention group
Group type: COMPARATOR
Intervention: Cracker consumption for 8 weeks
Number of subjects: 73
Study 38826471 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted group (clinicians reviewed machine learning predictions)
Number of subjects: 5071
Study 38826471 — intervention group
Group type: COMPARATOR
Intervention: Unassisted group (clinicians reviewed without machine learning predictions)
Number of subjects: 5071
Study 38826570 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard step-up conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs)
Number of subjects: 100
Study 38826570 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination csDMARDs (methotrexate with either sulfasalazine or leflunomide)
Number of subjects: 100
Study 38826570 — intervention group
Group type: EXPERIMENTAL
Intervention: Early biologics induction therapy (adalimumab plus methotrexate)
Number of subjects: 100
Study 38826616 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical grey matter volume in left superior frontal gyrus
Number of subjects: 30
Study 38826616 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor scores
Number of subjects: 30
Study 38826616 — intervention group
Group type: EXPERIMENTAL
Intervention: Conners 3 ADHD Index scores
Number of subjects: 30
Study 38826786 — intervention group
Group type: EXPERIMENTAL
Intervention: SPd-40 (selinexor 40 mg)
Number of subjects: 48
Study 38826786 — intervention group
Group type: EXPERIMENTAL
Intervention: SPd-60 (selinexor 60 mg)
Number of subjects: 48
Study 38827219 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolysed cow's milk protein-based infant formula (pHF)
Number of subjects: 288
Study 38827219 — intervention group
Group type: COMPARATOR
Intervention: Standard intact cow's milk protein-based formula (IPF)
Number of subjects: 288
Study 38827437 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (tDCS)
Number of subjects: 80
Study 38827437 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (tDCS)
Number of subjects: 80
Study 38827749 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1222 (ChAdOx1 nCoV-19) primary-series vaccination
Number of subjects: 2020
Study 38827749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2020
Study 38827798 — intervention group
Group type: EXPERIMENTAL
Intervention: Early urethral catheter removal after 24 hours
Number of subjects: 0
Study 38827798 — intervention group
Group type: COMPARATOR
Intervention: Delayed urethral catheter removal
Number of subjects: 0
Study 38827854 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Hydroxychloroquine (HC), Azithromycin (AZ), and Oseltamivir (OS)
Number of subjects: 471
Study 38827880 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 104
Study 38827880 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol + MgSO4 250mg
Number of subjects: 104
Study 38827880 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol + MgSO4 500mg
Number of subjects: 104
Study 38827880 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol + MgSO4 750mg
Number of subjects: 104
Study 38828023 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg HCTZ for four days
Number of subjects: 12
Study 38828023 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg henagliflozin for four days
Number of subjects: 12
Study 38828023 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg HCTZ + 10 mg henagliflozin for four days
Number of subjects: 12
Study 38828023 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (HCTZ + henagliflozin)
Number of subjects: 12
Study 38828109 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp)
Number of subjects: 660
Study 38828109 — intervention group
Group type: COMPARATOR
Intervention: Weekly chloroquine prophylaxis (CQ)
Number of subjects: 660
Study 38828482 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuune decision aid
Number of subjects: 310
Study 38828482 — intervention group
Group type: COMPARATOR
Intervention: Control aid
Number of subjects: 310
Study 38828522 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interview
Number of subjects: 396
Study 38828522 — intervention group
Group type: COMPARATOR
Intervention: SMS
Number of subjects: 396
Study 38828522 — intervention group
Group type: COMPARATOR
Intervention: Diary card
Number of subjects: 396
Study 38828563 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose edoxaban regimen (60/30 mg daily)
Number of subjects: 21105
Study 38828563 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose edoxaban regimen (30/15 mg daily)
Number of subjects: 21105
Study 38828563 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 21105
Study 38828679 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD risk estimation via a self-directed screening station implemented in 14 pathology service sites.
Number of subjects: 26
Study 38828679 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD risk estimation service integration into routine workflow at pathology services.
Number of subjects: 26
Study 38828895 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib
Number of subjects: 235
Study 38828895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study 38828933 — intervention group
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin, bortezomib, and dexamethasone (BVd)
Number of subjects: 494
Study 38828933 — intervention group
Group type: COMPARATOR
Intervention: Daratumumab, bortezomib, and dexamethasone (DVd)
Number of subjects: 494
Study 38828938 — intervention group
Group type: EXPERIMENTAL
Intervention: Once weekly paclitaxel
Number of subjects: 240
Study 38828938 — intervention group
Group type: COMPARATOR
Intervention: Once every 3 weeks docetaxel
Number of subjects: 240
Study 38828938 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk genotype
Number of subjects: 240
Study 38828938 — intervention group
Group type: COMPARATOR
Intervention: Low-risk genotype
Number of subjects: 240
Study 38828945 — intervention group
Group type: EXPERIMENTAL
Intervention: Crinecerfont
Number of subjects: 103
Study 38828945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 38828946 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 216
Study 38828946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 38828951 — intervention group
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin, pomalidomide, and dexamethasone (BPd)
Number of subjects: 302
Study 38828951 — intervention group
Group type: COMPARATOR
Intervention: Pomalidomide, bortezomib, and dexamethasone (PVd)
Number of subjects: 302
Study 38828955 — intervention group
Group type: EXPERIMENTAL
Intervention: Crinecerfont
Number of subjects: 182
Study 38828955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 38828959 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg osimertinib once daily
Number of subjects: 73
Study 38828957 — intervention group
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 0
Study 38828958 — intervention group
Group type: EXPERIMENTAL
Intervention: IV posaconazole 300 mg q12h and 300 mg q8h for the first two days, followed by 400 mg q24h maintenance
Number of subjects: 31
Study 38828958 — intervention group
Group type: COMPARATOR
Intervention: IV posaconazole 300 mg q24h
Number of subjects: 31
Study 38828984 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant ipilimumab plus nivolumab followed by surgery
Number of subjects: 423
Study 38828984 — intervention group
Group type: COMPARATOR
Intervention: Surgery followed by 12 cycles of adjuvant nivolumab
Number of subjects: 423
Study 38828984 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant ipilimumab plus nivolumab
Number of subjects: 423
Study 38829011 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-IVT strategy with tenecteplase 0.25 mg/kg
Number of subjects: 294
Study 38829011 — intervention group
Group type: COMPARATOR
Intervention: Single-IVT approach with alteplase
Number of subjects: 294
Study 38829281 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated analysis of thoraco-abdominal asynchrony using respiratory inductance plethysmography; parameters include phase angle, loop rotation, global phase delay, and loop area.
Number of subjects: 2290
Study 38829281 — intervention group
Group type: EXPERIMENTAL
Intervention: Global phase delay as a parameter for diagnosis and follow-up of clinical conditions leading to TAA.
Number of subjects: 2290
Study 38829396 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-counseling intervention
Number of subjects: 28
Study 38829396 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 28
Study 38829416 — intervention group
Group type: EXPERIMENTAL
Intervention: RTXM83-CHOP
Number of subjects: 27
Study 38829416 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 27
Study 38829437 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0
Study 38829437 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 0
Study 38829483 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Hyaluronic Acid (LMWHA)
Number of subjects: 36
Study 38829483 — intervention group
Group type: COMPARATOR
Intervention: High Molecular Weight Hyaluronic Acid (HMWHA)
Number of subjects: 36
Study 38829483 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 36
Study 38829506 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based neoadjuvant chemotherapy
Number of subjects: 210
Study 38829506 — intervention group
Group type: COMPARATOR
Intervention: Anthracycline-based neoadjuvant chemotherapy
Number of subjects: 210
Study 38829506 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Platinum-based vs Anthracycline-based
Number of subjects: 210
Study 38829609 — intervention group
Group type: EXPERIMENTAL
Intervention: HugeMed® videolaryngoscope (HVL)
Number of subjects: 88
Study 38829609 — intervention group
Group type: COMPARATOR
Intervention: Macintosh direct laryngoscope (MDL)
Number of subjects: 88
Study 38829616 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 60
Study 38829616 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal switch (DS)
Number of subjects: 60
Study 38829618 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring of BP and medication adherence (RM)
Number of subjects: 246
Study 38829618 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring of BP and medication adherence with social support (SS)
Number of subjects: 246
Study 38829618 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 246
Study 38829619 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Care (CC)
Number of subjects: 158
Study 38829664 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual weaning protocol (n=176) with additional 6 months of nighttime wear before stopping
Number of subjects: 369
Study 38829664 — intervention group
Group type: COMPARATOR
Intervention: Immediate weaning protocol (n=193) with immediate brace removal
Number of subjects: 369
Study 38829664 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual weaning protocol
Number of subjects: 369
Study 38829664 — intervention group
Group type: COMPARATOR
Intervention: Immediate weaning protocol
Number of subjects: 369
Study 38829692 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncoplastic partial mastectomy
Number of subjects: 340
Study 38829692 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial mastectomy
Number of subjects: 340
Study 38829692 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy with immediate reconstruction
Number of subjects: 340
Study 38829692 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 340
Study 38829703 — intervention group
Group type: EXPERIMENTAL
Intervention: Lademirsen, dosage and duration not available
Number of subjects: 0
Study 38829703 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study 38829821 — intervention group
Group type: EXPERIMENTAL
Intervention: +P (PCV13)
Number of subjects: 261
Study 38829821 — intervention group
Group type: COMPARATOR
Intervention: +S (PHiD-CV10)
Number of subjects: 261
Study 38829880 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent quality improvement (QI) strategy
Number of subjects: 1146
Study 38829880 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1146
Study 38829882 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO-Feeding Program (four weekly group-based training sessions led by healthcare professionals)
Number of subjects: 0
Study 38829882 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO-Feeding Program
Number of subjects: 0
Study 38829894 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA plaster 1
Number of subjects: 16
Study 38829894 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA plaster 2
Number of subjects: 16
Study 38829894 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA plaster 1 and 2
Number of subjects: 16
Study 38830030 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 rounds of fecal immunochemical testing (FIT) 2 years apart
Number of subjects: 90537
Study 38830030 — intervention group
Group type: COMPARATOR
Intervention: Primary colonoscopy
Number of subjects: 90537
Study 38830188 — intervention group
Group type: EXPERIMENTAL
Intervention: Topography-guided femtosecond LASIK
Number of subjects: 30
Study 38830189 — intervention group
Group type: EXPERIMENTAL
Intervention: DMEK
Number of subjects: 331
Study 38830189 — intervention group
Group type: COMPARATOR
Intervention: ConDSAEK
Number of subjects: 331
Study 38830189 — intervention group
Group type: COMPARATOR
Intervention: UT-DSAEK
Number of subjects: 331
Study 38830189 — intervention group
Group type: COMPARATOR
Intervention: ConDSAEK and UT-DSAEK
Number of subjects: 331
Study 38830303 — intervention group
Group type: EXPERIMENTAL
Intervention: platinum-pemetrexed-atezolizumab-bevacizumab (PPAB)
Number of subjects: 140
Study 38830303 — intervention group
Group type: EXPERIMENTAL
Intervention: platinum-pemetrexed-atezolizumab (PPA)
Number of subjects: 140
Study 38830375 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 μg VLA15
Number of subjects: 821
Study 38830375 — intervention group
Group type: EXPERIMENTAL
Intervention: 135 μg VLA15
Number of subjects: 821
Study 38830375 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 μg VLA15
Number of subjects: 821
Study 38830375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 821
Study 38830408 — intervention group
Group type: EXPERIMENTAL
Intervention: preg-MEDAS
Number of subjects: 812
Study 38830472 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt + honey with Bifidobacterium animalis subsp. lactis DN-173 010/CNCM I-2494
Number of subjects: 66
Study 38830472 — intervention group
Group type: COMPARATOR
Intervention: Control (no honey)
Number of subjects: 66
Study 38830735 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) administered as 1 g at skin incision, followed by an additional 1 g prior to skin closure.
Number of subjects: 0
Study 38830735 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo (control group).
Number of subjects: 0
Study 38830735 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA).
Number of subjects: 0
Study 38830741 — intervention group
Group type: EXPERIMENTAL
Intervention: WHOOP Arrhythmia Notification Feature (WARN) algorithm
Number of subjects: 0
Study 38830741 — intervention group
Group type: COMPARATOR
Intervention: BioTel ePatch (electrocardiography gold-standard)
Number of subjects: 0
Study 38830744 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education
Number of subjects: 82
Study 38830744 — intervention group
Group type: COMPARATOR
Intervention: Back school
Number of subjects: 82
Study 38830745 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-free anaesthesia (OFA) using dexmedetomidine and lidocaine
Number of subjects: 268
Study 38830745 — intervention group
Group type: COMPARATOR
Intervention: Opioid-based anaesthesia (OBA) using remifentanil
Number of subjects: 268
Study 38830745 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-free anaesthesia (OFA)
Number of subjects: 268
Study 38830745 — intervention group
Group type: COMPARATOR
Intervention: Opioid-based anaesthesia (OBA)
Number of subjects: 268
Study 38830904 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled Crohn's disease
Number of subjects: 22
Study 38830904 — intervention group
Group type: COMPARATOR
Intervention: Control group (no evident pathogenic abnormality)
Number of subjects: 22
Study 38830962 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 2 white kidney bean extract (WKBE HIGH) 1000 mg
Number of subjects: 81
Study 38830962 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 2 white kidney bean extract (WKBE LOW) 700 mg
Number of subjects: 81
Study 38830962 — intervention group
Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose)
Number of subjects: 81
Study 38830991 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel)
Number of subjects: 130